CYP2C19 and metabolic dysfunction-associated steatotic liver disease: Even a moderate progression of NAFLD (i.e. NAS from 0 to 4, fibrosis stage from 0 to 2, or steatohepatitis grade 0 to 1) results in a decrease of CYP2C19 to around 50%.